ADAlfredo Damasceno

Alfredo Damasceno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfredo Damasceno has a total of 255 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Education Research: Career, Research, and Mentorship Outcomes of an International Neuroimmunology Education Exchange Program

    by Cassia Elisa Marin, Bruna Leles Vieira de Souza, Vanessa Fernanda Moreira Ferreira, Joao Vitor Mahler, Nathane Braga, Milena Sales Pitombeira, Natalia Talim, Maria Fernanda Mendes, Vanessa Daccach Marques, Alfredo Damasceno, et al.

    Background and ObjectivesSubspecialty exchange programs in neuroimmunology are scarce and have not been formally evaluated. We assessed participant-reported outcomes of the Neuroimmunology Exchange...

  • Open Access

    NMOSD and MOGAD in Latin America: A consensus-informed regional perspective

    by Vinícius Boldrini, Sara Samadzadeh, Edgar Carnero Contentti, Vitória Pimentel, Natalia Szejko, Ethel Ciampi, Jacqueline Palace, Friedemann Paul, Jefferson Becker, Alfredo Damasceno, et al.

  • Benign multiple sclerosis: looking beyond physical disability

    by Josué de Almeida David, Thomas Vieira de Paula, Alfredo Damasceno

    Background Previous studies on Benign Multiple Sclerosis (BMS) relied mostly on the Expanded Disability Status Scale (EDSS) for classification. In addition, the underlying mechanisms of BMS are not yet fully understood. Therefore, we analyzed the frequency of BMS when parameters beyond EDSS are included, and BMS neuroimaging correlates. Methods BMS (EDSS ≤ 3.0 after 10 years of onset) and traditional MS (EDSS > 3.0 after the same period) individuals underwent assessment of physical disability, fatigue, depression, and cognition. BMS were further classified according to a stringent EDSS-based criteria (EDSS ≤ 2.0 after 15 years of onset) and as fully benign (no fatigue, depression or cognitive deficit). We quantified lesions in four locations for dissemination in space (DIS). Logistic regression was employed to analyze clinical/demographic and neuroimaging predictors of BMS. Results Individuals with traditional MS (n = 23) and BMS (n = 30) had similar frequency of depression. Thirteen (43.3%) BMS individuals had no fatigue, depression or cognitive deficit. Lesions at each DIS location were similarly distributed across groups, except for the spinal cord which was lower in BMS (p = 0.024). After logistic regression, education (OR = 0.839, 95%CI 0.716–0.984) and spinal cord lesions (OR = 1.364, 95%CI 1.054–1.765) were associated with BMS. Conclusions Individuals with the EDSS-based classification of BMS show a similar frequency of depression compared to traditional RRMS, underscoring the need of a broader definition of BMS. Higher education and less spinal cord lesions are associated with the BMS status.

  • Open Access

    2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children

    by Samira Luisa dos Apóstolos-Pereira, Alfredo Damasceno, Ana Claudia Piccolo, Maria Fernanda Mendes, Maria Lúcia Brito, Regina Alvarenga, Bruna Klein da Costa, Douglas Kazutochi Sato, Doralina Guimarães Brum, Elisa Mello, et al.

    Neuromyelitis optica spectrum disorder (NMOSD) is a debilitating recurrent inflammatory disease of the central nervous system. Establishing management guidelines is essential to optimize patient care in Brazil. To combine the Delphi and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approaches to validate evidence-based guideline statements for NMOSD treatment. These guidelines focused on providing recommendations for different scenarios: general management and diagnosis of NMOSD; acute and preventive treatments (including systemic immunosuppressants and anti-B cell, anti-interleukin-6, and anti-complement monoclonal antibodies); and therapeutic approaches in special groups (such as the pediatric population and pregnant women). A literature review based on the Population, Intervention, Comparator, and Outcome (PICO) framework was performed, and studies were evaluated using the GRADE system. An initial questionnaire containing 19 statements was sent to 44 specialists from all regions of Brazil. Three voting rounds were necessary to reach consensus in all statements. After the first voting round, 17 statements reached consensus (level of agreement > 70%). Two statements failed to reach consensus and were, thus, revised. One of them was segmented into three different statements. After the second voting round, three out of the four revised statements reached consensus. Upon further revision, the last statement was again submitted to voting, reaching consensus in this third round. Overall, agreement was achieved on the 21 proposed statements. The primary objective in the management of NMOSD is to mitigate the severity of the attacks and prevent relapses, thereby minimizing the risk of irreversible neurological deficits. The statements in the current guideline offer evidence-based recommendations for such management within the Brazilian context.


  • Open Access

    Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database

    by Alfredo Damasceno, Cintia Ramari, Carlos Tauil, Henry Koiti Sato, Dagoberto Callegaro, Maria Fernanda Mendes, José Artur Costa D'ALmeida, Denise Sisterolli Diniz, Osvaldo J. M. Nascimento, Laura Parolin, et al.

    Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.


  • Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders

    by Gabriel de Deus Vieira, Vinícius Oliveira Boldrini, Simone Mader, Tania Kümpfel, Edgar Meinl, Alfredo Damasceno


  • Open Access

    Cortical ribbon sign on neuroimaging in a patient with hepatic encephalopathy secondary to herbal medicine usage

    by Gabriel de Deus Vieira, Mariana Moreira Soares de Sá, Arthur de Medeiros Dias, Rafael Gemaque Lima Bentes, Augusto Celso Scarparo Amato, André Augusto Lemos Vidal de Negreiros, Ana Carolina Amaral de Andrade, Simone Reges Perales, Elaine Cristina de Ataide, Alexandre Foratto, et al.

    The use of herbal medicines is growing exponentially despite the lack of scientific evidence regarding their effectivity and toxicity. ( , ) Moreover, the use of herbal medicines have been reported to be common in patients with chronic liver disease (30–62%); these medicines can lead to hepatotoxicity and serious hepatic side effects. ( ) Hepatic encephalopathy is a complication of acute liver failure and chronic liver disease that causes cognitive dysfunction, motor deficits, and seizures. ( , ) Gastrointestinal hemorrhage,

  • Open Access

    Nonalcoholic Wernicke encephalopathy with petechial hemorrhage in the tectal region

    by Gabriel de Deus Vieira, Augusto Celso Scarparo Amato Filho, Alfredo Damasceno

    A 39-year-old woman, after an episode of acute appendicitis, developed necrosis and intestinal obstruction, requiring colectomy and ileostomy. After hospital discharge, she had a high output through the ileostomy and low food intake. A few months later, she developed bilateral nystagmus, ataxic syndrome and difficulty concentrating. Susceptibility weighted imaging (SWI) sequence of the brain magnetic resonance imaging (MRI) showed hypointensities in the mammillary bodies and inferior colliculi, which might represent microbleeds ([Figure 1]). Wernicke encephalopathy (WE) usually affects the mamillary bodies, thalami, and periaqueductal region. Rare hemorrhagic manifestations are reported in the literature, most in the mamillary bodies. The breakdown of the blood-brain barrier may contribute to this petechial hemorrhage in WE.[1] [2] All authors contributed equally to the present work. Received: 05 January 2023 Accepted: 25 February 2023 Article published online: 30 August 2023 © 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil